Acurx reports Q3 net loss of $3.1M; ibezapolstat Phase 2 shows 96% cure rate, advancing to Phase 3

Acurx Pharmaceuticals, Inc.

2023-Q3 EPS reported -$0.77

Net loss $3.1M ($0.24/diluted share) vs $3.5M ($0.32) in Q3 2022; cash $7.1M at Sept 30, 2023.
Post-quarter warrant conversion raised $2.2M via ~680,000 shares issued.
Ibezapolstat Phase 2 top-line: 96% (25/26) clinical cure rate at end of treatment; no safety concerns.
Company preparing for End-of-Phase 2 FDA meeting and Phase 3 initiation.
R&D expenses $1.3M in Q3 (down from $1.6M); G&A $1.8M (down from $2.0M).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Acurx Pharmaceuticals, Inc. reported third quarter ended September 30, 2023 results: net income $3.1 million or $0.24 per diluted share.

Period: third quarter ended September 30, 2023
Net income: $3.1 million or $0.24 per diluted share
Result: reported results

Exact text from the filing

The Company reported a net loss of $3.1 million or $0.24 per diluted share for the three months ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

Acurx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-118064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.